Phillip Liu

Senior Vice President, Head of Biology at Synnovation Therapeutics

Phillip Liu has a diverse work experience spanning various roles in the pharmaceutical and biotechnology industry. Phillip is currently the Senior Vice President and Head of Biology at Synnovation Therapeutics since November 2022. Prior to that, from February 2022 to November 2022, they worked as an Independent Consultant.

Before joining Synnovation Therapeutics, Phillip held the position of Executive Director, Oncology Biology at Kymera Therapeutics from October 2019 to February 2022. Phillip also had a long tenure at Incyte, where they held multiple roles including Senior Director, Director, Associate Director, Senior Principal Investigator, Principal Investigator, and Senior Research Investigator. Phillip was associated with Incyte from 2002 to 2019.

Phillip began their career as a Senior Research Scientist at Bristol-Myers Squibb (previously DuPont Pharmaceuticals) in 2001. Prior to that, they were a Post-doctoral Fellow at the University of Michigan Medical School from June 1996 to May 2001, where they worked under the guidance of Dr. Dennis J. Thiele.

Overall, Phillip Liu has extensive experience in biology, oncology, and research, with notable leadership positions in their career.

Phillip Liu obtained a Ph.D. in Pharmacology & Toxicology from the University of California, Davis, having attended from 1990 to 1996. Prior to that, they pursued an M.F.S. degree in Environmental Studies at Yale University, attending from 1988 to 1990. Phillip completed their undergraduate education at Oberlin College, where they received a B.A. in Chemistry from 1980 to 1984.

Location

Philadelphia, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Synnovation Therapeutics

Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.


Employees

11-50

Links